Establishment of a liquid biopsy-based model that allows robust prediction of response to neoadjuvant therapy (NAT) in ESCC patients (IMAGE)

Tokyo Medical and Dental University

Establishment of a liquid biopsy-based model that allows robust prediction of response to neoadjuvant therapy (NAT) in ESCC patients

Caption

NAT resistance risk (NATRR) model were generated using 3 mRNAs signature, 4 miRNAs signature, and key clinocopathological facters, followed by PCR-based validation in surgical tissue specimens. NATRR model were finally applied to a liquid biopsy assay by analyzing pretreatment serum specimens.

Credit

Department of Gastrointestinal Surgery, TMDU

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.